文献速递肿瘤 PET/CT骨显像与常规 SPECT

治疗前18F-FDG PET/CT联合克隆性循环浆细胞定量构建新诊断多发性骨髓瘤风险模型

Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-01-28

该回顾性研究纳入163例接受新药诱导治疗的新诊断症状性多发性骨髓瘤患者,联合治疗前PET/CT表现与循环浆细胞水平建立PET-CPC分期系统。三组患者无进展生存和总生存差异显著,且在多因素分析中保持独立预后价值。

要点

  • 高危PET/CT定义为>3个局灶性病变伴或不伴髓外病变,高CPC定义为≥0.10%单核细胞。
  • PET-CPC III期患者中位PFS 15.9个月、中位OS 40.4个月,预后最差。
  • 该分期在年龄、R-ISS分期及高危细胞遗传学亚组中均可区分PFS和OS。

核心结论

  • PET-CPC分期系统可独立于既有危险因素预测新诊断多发性骨髓瘤患者的无进展生存和总生存。

研究设计与样本

  • 回顾性分析163例连续的新诊断症状性多发性骨髓瘤患者,均在接受含新药的诱导治疗前完成PET/CT和循环浆细胞定量。

主要发现

  • PET-CPC I、II、III期的中位PFS分别为未达到、36.4个月和15.9个月,中位OS分别为未达到、未达到和40.4个月,PFS和OS的P值均<0.001。
  • 该分期在年龄<75岁或≥75岁、R-ISS II或III期、伴或不伴高危细胞遗传学特征的患者中均可区分PFS和OS。
  • 多因素分析显示PET-CPC分期系统对PFS和OS仍具预后价值。

关键数值与推荐

  • 高危PET/CT findings定义为存在>3个局灶性病变,伴或不伴髓外病变。
  • CPC水平升高定义为克隆性循环浆细胞≥0.10%的总单核细胞。
  • PET-CPC I期为无高危PET/CT表现且CPC低水平;III期为有高危PET/CT表现且CPC高水平;II期为其余患者。

临床怎么用

  • 治疗前可联合18F-FDG PET/CT与循环浆细胞定量进行PET-CPC分期,辅助识别高危患者以支持风险 adapted 治疗探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Both 18F-FDG PET/CT and clonal circulating plasma cell (CPC) quantification are emerging tools for multiple myeloma (MM) prognostication that have been validated in recent studies. This study investigated the value of PET/CT coupled with CPC quantification for MM prognostication that may contribute to future risk-adapted treatment. METHODS: We retrospectively analysed the prognostic relevance of a combination of pretreatment PET/CT findings and CPC levels in 163 consecutive patients with newly diagnosed, symptomatic MM receiving novel agents during induction therapies. RESULTS: High-risk PET/CT findings and elevated CPC levels were defined by the presence of >3 focal lesions with or without extramedullary disease and CPCs ≥0.10% of the total mononuclear cells evaluated, respectively. Subsequently, patients were divided into three groups: PET-CPC stage I included patients with no high-risk PET/CT findings and low CPC levels; stage III included patients with high-risk PET/CT findings and high CPC levels; and stage II included the remaining patients. The three groups of patients differed significantly in terms of both progression-free survival (PFS) and overall survival (OS) (median PFS: not reached [NR] and 36.4 and 15.9 months, and median OS: NR, NR, and 40.4 months for stages I, II, and III, respectively; P < 0.001 for both PFS and OS). This system discriminated both PFS and OS even among younger (age < 75 years) or older (≥ 75 years) patients, patients with Revised International Staging System stage II or III, and patients with or without high-risk cytogenetic characteristics. In the multivariate analysis, the PET-CPC staging system remained prognostic for both PFS and OS. CONCLUSIONS: The PET-CPC staging system predicted survival outcomes independently of established risk factors in patients with newly diagnosed MM. Pretreatment 18F-FDG PET/CT assessment combined with CPC quantification may improve the prognostication of MM and facilitate the development of novel risk-adapted approaches for MM.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Abe Y, Narita K, Kobayashi H, et al. Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging. 2019. PMID: 30687892. doi:10.1007/s00259-019-4275-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。